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Method
Bisulfite Patch PCR enables multiplexed sequencing
of promoter methylation across cancer samples
Katherine Elena Varley and Robi David Mitra1
Department of Genetics, Center for Genome Sciences, Washington University School of Medicine, St. Louis, Missouri 63108, USA
Aberrant DNA methylation frequently occurs at gene promoters during cancer progression. It is important to identify
these loci because they are often misregulated and drive tumorigenesis. Bisulfite sequencing is the most direct and highest
resolution assay for identifying aberrant promoter methylation. Recently, genomic capture methods have been combined
with next-generation sequencing to enable genome-scale surveys of methylation in individual samples. However, it is
challenging to validate candidate loci identified by these approaches because an efficient method to bisulfite sequence
more than 50 differentially methylated loci across a large number of samples does not exist. To address this problem, we
developed Bisulfite Patch PCR, which enables highly multiplexed bisulfite PCR and sequencing across many samples. Using
this method, we successfully amplified 100% of 94 targeted gene promoters simultaneously in the same reaction. By
incorporating sample-specific DNA barcodes into the amplicons, we analyzed 48 samples in a single run of the 454 Life
Sciences (Roche) FLX sequencer. The method requires small amounts of starting DNA (250 ng) and does not require
a shotgun library construction. The method was highly specific; 90% of sequencing reads aligned to targeted loci. The
targeted promoters were from genes that are frequently mutated in breast and colon cancer, and the samples included
breast and colon tumor and adjacent normal tissue. This approach allowed us to identify nine gene promoters that exhibit
tumor-specific DNA methylation defects that occur frequently in colon and breast cancer. We also analyzed single
nucleotide polymorphisms to observe DNA methylation that accumulated on specific alleles during tumor development.
This method is broadly applicable for studying DNA methylation across large numbers of patient samples using next-
generation sequencing.
[Supplemental material is available online at http://www.genome.org.]
Inappropriate CpG DNA methylation has been found in most
types of cancer (Lyko and Brown 2005), and many genes involved
in malignancy can acquire aberrant promoter methylation (Baylin
et al. 1998). Tumor suppressor genes frequently exhibit promoter
hypermethylation, an epimutation that is associated with in-
appropriate gene silencing (Baylin et al. 1998). A recent study has
found that several key tumor suppressor genes exhibit promoter
hypermethylation more often than genetic disruption, suggesting
this mechanism is an important driver of tumorigenesis (Chan
et al. 2008). Oncogenes can exhibit hypomethylation of their
promoters, which is associated with inappropriate expression (Jun
et al. 2009). More complicated misregulation of a gene can also
be caused by aberrant methylation; a recent report found that
hypermethylation of a p53 binding site blocked binding of the
repressor, resulting in overexpression of the survivin oncogene
(Nabilsi et al. 2009).
The identification of gene promoters that are aberrantly
methylated during tumor development is valuable because it
provides information about the biological pathways that are
commonly disrupted during tumorigenesis (Klarmann et al. 2008;
Suzuki et al. 2008). This knowledge may ultimately lead to new
drug targets. Analysis of promoter methylation can also classify
distinct subtypes of cancers that may have differential clinical
characteristics in order to personalize treatment (Esteller et al.
2000; Widschwendter et al. 2004). Finally, loci that are hyper-
methylated in tumors are often detected in peripheral samples
(e.g., blood or stool) and may serve as diagnostic or prognostic
biomarkers (Laird 2005).
Many techniques have been developed to detect DNA meth-
ylation, includingmethods based onmicroarrays (Ushijima 2005),
quantitative PCR (Eads et al. 2000), mass spectrometry (Ehrich
et al. 2005), and DNA sequencing (Frommer et al. 1992). The
method that is the most direct and has the highest resolution in-
volves the treatment of genomic DNA with sodium bisulfite
(which converts unmethylated cytosines to uracil, while leaving
methylated cytosines intact) followed by the sequencing of single
molecules. This method is capable of detecting any cytosine DNA
methylation, including the non-CpG cytosine methylation found
in stem cells (Lister et al. 2009). Not only does this method de-
termine the methylation state at each cytosine across a single
molecule, but it also detects single nucleotide polymorphisms
(SNPs). This cis information makes it possible to distinguish allele-
specific methylation (Frommer et al. 1992). This cis information
is also valuable for quantifying rare densely methylated mole-
cules in a background of unmethylated or sparsely methylated
molecules.
The recent introduction of second-generation DNA se-
quencing technologies has significantly reduced the cost required
to sequence DNA. This has led to several new approaches for
studying aberrant methylation using bisulfite PCR and sequenc-
ing. Methods for genome-wide surveys of methylation have been
developed, including whole-genome bisulfite sequencing (Cokus
et al. 2008; Lister et al. 2009), bisulfite sequencing large fractions of
restriction digested genomic DNA (Meissner et al. 2008), padlock
probe-based strategies (Ball et al. 2009; Deng et al. 2009), and array-
based hybridization capture (Hodges et al. 2009). These methods
are powerful because they cast a wide net and can generate many
1Corresponding author.
E-mail rmitra@genetics.wustl.edu.
Article published online before print. Article and publication date are at
http://www.genome.org/cgi/doi/10.1101/gr.101212.109.
20:1279–1287  2010 by Cold Spring Harbor Laboratory Press; ISSN 1088-9051/10; www.genome.org Genome Research 1279
www.genome.org
 Cold Spring Harbor Laboratory Press on December 17, 2013 - Published by genome.cshlp.orgDownloaded from 
novel hypotheses. However, in order to identify epimutations that
are significantly associated with a disease, it is usually necessary to
analyze hundreds of samples, something that remains cost-pro-
hibitive with genome-scale methods. It is possible to analyze a few
loci across many samples by amplifying each locus individually,
labeling with sample-specific barcodes, and performing ultra-deep
bisulfite sequencing (Taylor et al. 2007; Korshunova et al. 2008;
Varley et al. 2009). However, these methods are limited to a small
number of loci because the amplification of each locus separately
is laborious and requires a significant amount of patient DNA
per locus queried. Thus, there is a need for methods that enable
the targeted multiplexed bisulfite PCR and sequencing of an in-
termediate number of loci (100–1000) across a large number of
samples.
We sought to develop a method to perform highly multi-
plexed bisulfite sequencing across many patient samples simulta-
neously. We based our design on the Nested Patch PCR method
that we developed for the multiplexed sequencing of loci to
identify genetic mutations (Varley and Mitra 2008). Several key
steps had to be modified to be compatible with the bisulfite
treatment of genomic DNA. Bisulfite treatment significantly re-
duces the complexity of DNA sequence by converting most Cs to
Ts. It also results inmolecules from the same locus having different
sequences depending on their methylation state. Therefore we
perform the oligo hybridization and ligation-based selection of the
targeted loci before the bisulfite treatment. The selection is highly
sensitive and specific, and only one pair of oligos per locus is
needed, even when selecting CpG-rich loci. The PCR amplifica-
tion of selected loci is performed after the bisulfite. Therefore
the universal primers used to amplify all loci simultaneously had
to be designed to exclude Cs, so that they would remain un-
changed through the bisulfite conversion. Since the major ap-
plication of this method is likely to be in clinical specimens, we
optimized the method so that it did not
require large quantities of starting ge-
nomic DNA and was compatible with
the DNA degradation inherit in the so-
dium bisulfite treatment.
We designed the method to be easy
to implement in any laboratory with
standard molecular biology techniques
and reagents. We also tested that it would
scale up well to process many patient
samples in 96-well format. We integrated
sample-specific DNA barcodes into the
multiplexed amplification so that many
patient samples can be pooled and se-
quenced simultaneously on second-gen-
eration sequencing machines. Here, we
present a proof-of-principle experiment
in which we amplified promoter regions
from 94 targeted loci simultaneously and
sequenced these loci across 48 samples,
including colon and breast tumor and
adjacent normal tissue samples. In this
experiment, we characterized the pro-
moter methylation of genes that are
known to be frequently mutated in can-
cer. We identified several novel loci that
undergo frequent tumor-specific pro-
moter methylation, and we observed
allele-specific methylation patterns that
occur during tumor development. We demonstrated that this
method uses the power of next-generation sequencing to study
DNA methylation at many loci across many patient samples.
Results
Overview of Bisulfite Patch PCR
Bisulfite Patch PCR begins with a restriction digest of human ge-
nomic DNA to define the ends of the fragments that will be se-
lected (Fig. 1A,B). Targeted loci are then selected from the genomic
restriction fragments by annealing patch oligos to the ends of the
targeted genomic fragments. These oligos serve as a patch between
the correct fragments and universal primers (U1 and U2) (Fig. 1C).
The universal primers are then ligated to the genomic fragments
using a thermostable ligase (Fig. 1D). Unselected genomic DNA
is then degraded with exonucleases to gain additional selectivity
(Fig. 1E). Selected fragments are protected from degradation by
a 39 modification on the universal primer U2 (Fig. 1E). Next, the
selected fragments are treated with sodium bisulfite to convert un-
methylated cytosines to uracil, leaving themethylated bases intact
(Fig. 1F). The universal primers do not contain cytosine bases so
that the sequence remains unchanged through the bisulfite con-
version. The bisulfite-treated selected fragments are then all am-
plified together simultaneously by PCR with the universal primers
(U1 and U29) (Fig. 1G). Sample-specific DNA barcodes are in-
corporated into the universal primers by tailing the 59 end with
a DNA sequence that is specific to each sample and the sequencing
platform primers (454 Life Sciences [Roche] sequencing primers)
(Fig. 1G). The final PCR amplicons from each of the samples can be
pooled together for sequencing because the first few bases of each
sequencing readwill identify the sample fromwhich that sequence
originated.
Figure 1. Bisulfite Patch PCR. (A,B) Genomic DNA restriction digest. (C ) Anneal patch oligos and
universal primers specifically to the ends of desired fragments. (D) Ligate universal primers (U1 and U2)
to targeted fragments. (E ) Degrade unselected DNA with exonucleases. Targeted loci are protected
from exonuclease by 39 modification on U2. (F ) Treat with sodium bisulfite to convert unmethylated
cytosine to uracil, leaving methylated cytosine intact. (G) PCR all loci simultaneously with universal
primers tailed with sample-specific DNA barcodes and sequencing machine primers (454A and 454B).




 Cold Spring Harbor Laboratory Press on December 17, 2013 - Published by genome.cshlp.orgDownloaded from 
Highly multiplexed bisulfite sequencing of CAN gene
promoters in colon and breast cancer
To test the performance of Bisulfite Patch PCR, we analyzed the
promoter methylation of 94 genes that are frequently mutated in
breast and colon cancers (‘‘CAN genes’’) (Wood et al. 2007). We
designed the patch oligos to select AluI restriction digest fragments
containing at least three CpG positions within 700 bp upstream of
the transcription start site (TSS). We chose 42 colon CAN gene
promoters, 44 breast CAN gene promoters, four gene promoters
that were identified as both colon and breast CAN genes, and four
controls. The four controls include an imprinted locus, a house-
keeping gene promoter, and two neutral loci that accumulate
methylation with mitotic cell division (Kim et al. 2006). These
targeted promoter regions ranged in length from 125–581 bp
and totaled 25.4 kbp (Supplemental Data 1). To determine the
amount of genomic DNA required for Bisulfite Patch PCR, we
performed gel electrophoresis of the PCR products generatedwith
different amounts of starting DNA. We observed DNA within the
expected size range from reactions that started with as much as
1 mg and as little as 20 ng of human genomic DNA (Supplemental
Fig. 1).
We performed Bisulfite Patch PCR on 250 ng of genomicDNA
from each of the 48 samples in parallel in a 96-well plate. The ge-
nomic DNA was isolated from a panel of 12 colon tumors, 12
matched adjacent normal colon tissues, 12 breast tumors, and 12
matched adjacent normal breast tissues (Supplemental Table 2).
We incorporated a 5-bp sample-specific DNA barcode in the final
PCR, pooled the amplicons from all of the samples, and sequenced
the pool using the 454 Life Sciences (Roche) FLX sequencer. We
obtained 97,115 reads and aligned these to the in silico bisulfite-
treated reference sequences of our targeted loci. We successfully
amplified all 94 (100%) of the targeted loci, indicating that the
method ishighly sensitive.Ninety percent (87,458 reads) of all reads
mapped to one of the targeted promoters, demonstrating that the
method is highly specific. These results demonstrate that Bisulfite
Patch PCR enables highly multiplexed bisulfite sequencing.
Coverage of promoters and reproducibility
To analyze the uniformity of the sequence coverage, we graphed
the number of reads obtained for each targeted promoter versus
the length of the targeted region. (Fig. 2A; Supplemental Table 1).
The abundance of eachpromoter ranged from10 to 5114 reads.We
calculated that 93% of the promoters have coveragewithin 10-fold
of the median coverage (444 reads). The Pearson’s linear correla-
tion coefficient between the amplicon length and the number of
reads is0.65, suggesting that longer amplicons are less abundant
in the reaction. To determine if the observed correlation was sta-
tistically significant, we transformed the correlation to create a
t-statistic having N  2 degrees of freedom, and found that P <
1.3 3 1012. If we had restricted our design to a maximum target
length of 300 bp, then 92% (57/62) of those promoters would have
coverage within fivefold of the median coverage (1051 reads), so
approximately half of the variation in abundance of the loci is
attributable to length bias. We suspect that this length bias is in-
troduced by the bisulfite treatment, rather than by themultiplexed
PCR, since we did not observe a correlation between amplification
efficiency and length when performing the Nested Patch PCR
(Varley and Mitra 2008), which does not use bisulfite treatment.
Consistent with this hypothesis, others have observed that longer
DNA fragments are more likely to be damaged during the bisulfite
conversion (Munson et al. 2007).
To test if Bisulfite Patch PCR reproducibly amplifies selected
loci, we calculated the number of reads per locus in each of the 48
samples that were prepared in parallel. We then calculated the
correlation coefficient for the number of reads per locus between
all possible pairs of samples. The histogram of correlation co-
efficients obtained for the pairwise correlations between all 48
samples is shown in Figure 2B. The mean correlation coefficient is
0.91, indicating that the number of reads per locus is highly re-
producible across patient samples. This indicates that the abun-
dance of each locus in the reaction is not stochastic but represents
something intrinsic to the locus, including the length, as discussed
above.
Figure 2. Method performance. (A) Number of sequencing reads per promoter for all 94 targeted promoters, order by length in base pairs (bp) on the
x-axis. Longer promoter amplicons yield fewer sequencing reads (length bias), but 87 amplicons (93%) have coverage within 10-fold of the median
coverage (444 reads). The abundance of each promoter ranged from 10 to 5114 reads. (B) Histogram of the pairwise squared correlation coefficients for
the number of reads per promoter for all 48 samples. The mean correlation coefficient is 0.91, indicating that the number of reads per promoter is highly
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Methylation detection at control loci
To ensure that themultiplexed PCR aspect of
Bisulfite Patch PCR did not diminish the
ability to accurately detect methylation, we
examined the bisulfite sequence at control
loci. There was no DNA methylation de-
tected at the negative control promoter of
the housekeeping gene HSP90AB1 (NM_
007355), indicating the sodium bisulfite
conversion was effective. We did detect
methylation at all three (100%) of the posi-
tive control loci, including the H19 im-
printed promoter (AK311497) and two neu-
tral loci that accumulated DNA methylation with mitotic division
(NM_006941 Exon 2, and NM_004387 39 untranslated region
[UTR]) (Kim et al. 2006). These results led us to conclude the
method could accurately detect methylation patterns, which
agrees with previously published work in which methylation
patterns obtained by bisulfite sequencing using 454 Life Sciences
(Roche) sequencing were extensively validated (Taylor et al. 2007;
Korshunova et al. 2008; Varley et al. 2009).
Next, we sought to determine if the methylated and unmeth-
ylated molecules from the same locus are amplified with similar
efficiencies. This is required if the method is to be used to make
quantitative measurements of promoter methylation. The im-
printed region from the H19 locus (AK311497), which was in-
cluded as a control, allows the direct comparison of the amplifi-
cation efficiency of the methylated and unmethylated alleles. We
identified nine patients in our panel who were heterozygous for
a SNP (rs2251375) in the H19 locus. We used this SNP to identify
allele-specific methylation and to quantify the number of se-
quencing reads obtained for each allele. Allele-specific methyla-
tion was observed, and both alleles were amplified with nearly
equal efficiencies (Fig. 3). Imprintingmethylationwas observed on
either allele in different individuals, consistent with the parent-of-
origin determining which allele is methylated. Both alleles were
represented at similar frequencies—on average 42% of the se-
quencing reads corresponded to the ‘‘G’’ allele; 58%, to the ‘‘T’’
allele. Thus, our method amplifies the methylated and un-
methylated molecules from the same locus with nearly equal ef-
ficiency, which is crucial for quantifying heterogeneous methyla-
tion within tumors.
CAN gene promoter methylation
We next examined the methylation patterns found at the targeted
CAN gene promoters to determine if they exhibited tumor-specific
methylation. Since these genes were previously shown to be fre-
quentlymutated in colon and breast tumors (Wood et al. 2007), we
hypothesized that the promoters of these genes might also be
frequently hyper- or hypomethylated in these cancers. Promoter
classification was straightforward, as the vast majority of sequenc-
ing reads were either fully methylated or completely unmethylated
(Supplemental Fig. 2). We found that approximately half (51/94),
of all the promoters were unmethylated in all the tissue types that
we tested. Approximately one-third (34/94), of all promoters were
methylated in both cancer and normal tissue. The remaining nine
promoters exhibited tumor-specificmethylation (for summary, see
Table 1; for details, see Supplemental Table 1).
Tumor-specific promoter methylation
Of the nine promoters that exhibited tumor-specific methylation,
five were promoters from colon CAN genes, two were promoters
from breast CAN genes, and two were promoters from genes that
were frequently mutated in both colon and breast cancer (‘‘dual
CAN genes’’) (for summary, see Table 1; for details, see Supple-
mental Table 1).
Five promoters exhibited tumor-specific hypermethylation in
both breast and colon tumors (IGFBP3, UHRF2, LAMA1, ICAM5,
PPM1E). One promoter (SORL1) exhibited tumor-specific hypo-
methylation in both types of cancer. The methylation patterns of
ICAM5 and LAMA1 are shown in Figure 4, A and B, respectively.
Tumor-specific promoter methylation of ICAM5 (Chan et al. 2008)
and IGFBP3 (Tomii et al. 2007) was recently reported in different
cohorts of breast and colon cancers. The other three loci are novel
observations of aberrant tumor methylation. The frequent hyper-
methylation of these five loci in both types of tumors indicates
that common molecular defects are shared between colon and
breast cancer. The molecular defect could be an error in both types
of tumors that directs methylation to these loci, or it could suggest
that the inactivation of these genes is a key step in tumorigenesis in
both tissues.
These five loci that are hypermethylated in both breast and
colon cancer are methylated in 25%–75% of tumors (Table 2). Loci
that exhibit frequent tumor-specific methylation are often useful
Figure 3. Methylation at the H19 imprinted locus. Data from four pa-
tients whowere germline heterozygous for a SNP (rs2251375) in this locus.
The sequencing reads are aligned as rows in each panel. Each base in the
read is color-coded to indicate the sequence: (yellow) a methylated cyto-
sine; (blue) all other bases. The position of the SNP is indicated by the red
and white column: (red base) reads from the G allele; (white base) reads
from the T allele. The percentage of reads for each patient that are from the
G allele is listed below the patient identifier for each sample. As expected for
an imprinted locus, methylation is observed on one allele in both the tumor
(left panels) and the adjacent normal tissue (right panels) for each patient.
Both alleles and both methylated and unmethylated molecules were am-
plified and sequenced efficiently from this locus in all samples.






CAN genes Controls Total
Unmethylated 22 26 2 1 51
Methylated in tumor
and normal tissues
15 16 0 3 34
Tumor-specific methylation
Breast and colon 2 2 2 0 6
Colon 2 0 0 0 2
Breast 1 0 0 0 1




 Cold Spring Harbor Laboratory Press on December 17, 2013 - Published by genome.cshlp.orgDownloaded from 
as clinical biomarkers. A valuable biomarker would occur fre-
quently in patients’ tumors andwould be easily distinguished from
normal samples. We calculated the sensitivity and specificity of
these loci across our samples. The presence of aberrant methyla-
tion at two or more of these five methylated markers is found in
nine out of 12 breast tumors (75%), 11 out of 12 colon tumors
(92%), one of 12 normal breasts (8%), and
one of 12 normal colons (8%). These
strong classifiers of cancer versus normal
samples are good candidates for follow-
up studies to evaluate their potential as
biomarkers for stratifying disease sub-
types or as diagnostic biomarkers that can
be detected in peripheral specimens. The
frequency of aberrant methylation at
these loci approaches the significance of
even the most common genetic muta-
tions such as APC or TP53 mutations,
which are reported to occur in 40%–80%
of tumors (Sjoblom et al. 2006). This sup-
ports the previously proposed hypothesis
that epigenetic defects at CAN genes may
be more frequent than genetic mutations
(Chan et al. 2008).
Three of the CAN gene promoters
show tumor-specific methylation in only
one type of cancer. Colon tumor-specific
methylation was found in the promoters
of KCNQ5 (NM_019842) and CLSTN2
(NM_022131), and thosemethylation pat-
terns are shown in Figure 4, C and D, re-
spectively. Breast tumor-specific methyl-
ation was found in the promoter of APC
(NM_000038). The frequency of these
aberrant events in each tumor type is
cataloged in Table 2 and suggests that
these loci may represent frequent tumor-
specific epimutations that merit follow-
up investigation in a larger cohort of
tumors and adjacent normal and cancer-
free patient’s tissue.
Allelic tumor methylation
The single molecule resolution of bisul-
fite sequencing allows us to simulta-
neously assess themethylation status and
identify SNPs. As seen in Figure 5, we can
distinguish whether tumor-specific meth-
ylation is occurring on one allele or on
both alleles in individuals that are het-
erozygous for the SNP (rs2854744) in
IGFBP3 (NM_000598). Although some ab-
errant promoter methylation events are
known to always occur on both alleles,
such as MLH1 promoter methylation
(Veigl et al. 1998), we found examples in
which aberrant methylation was ob-
served on only one allele: Breast cancer
patient 4 acquired tumor-specific meth-
ylation primarily on the A allele, while
colon cancer patient 6 acquired tumor-
specific methylation primarily on the C allele (Fig. 5). However,
other patients acquired aberrant methylation on both alleles dur-
ing tumorigenesis, such as breast cancer patient 6 and colon cancer
patient 7 (Fig. 5). If associated with silencing, this biallelic meth-
ylation would indicate that both copies of the gene are inac-
tive. Some patients exhibit different allelic methylation patterns
Figure 4. Four promoters that exhibit tumor-specific methylation. Sequencing reads from all patients
for each type of tissue are grouped together in panels; breast tumors, adjacent normal breast tissues,
colon tumors, and adjacent normal colon tissues. The sequencing reads are aligned as rows in each
panel and are grouped by patient. Each base in the read is color-coded to indicate the sequence:
(yellow) a methylated cytosine; (blue) all other bases. (A,B) ICAM5 and LAMA1 promoters exhibit colon
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between their tumor and the adjacent normal tissue: Colon cancer
patient 12 hasmethylation on their A allele across all CpGs in both
the tumor and the adjacent normal tissue, but as the tumor
formed, the C allele acquired methylation, specifically in the re-
gion of the promoter most distal from the SNP. This suggests that
the accumulation of methylation on each allele can occur in dif-
ferent regions of the locus and can occur at different times in tu-
mor development. This type of allelic analysis is useful for re-
solving intratumorheterogeneity ofDNAmethylation, identifying
heterozygous and homozygous epimutations, and understand-
ing the accumulation of aberrant DNA methylation in different
tumors.
Discussion
Several methods have been developed to
perform the genome-wide profiling of
DNA methylation in individual samples.
These methods include genome-wide
surveys of methylation such as whole-
genome bisulfite sequencing (Cokus et al.
2008; Lister et al. 2009) and bisulfite se-
quencing large fractions of restriction
digested genomic DNA (Meissner et al.
2008) or methods that target specific
subclasses of loci such as padlock probe-
based strategies (Ball et al. 2009; Deng
et al. 2009) and array-based hybridiza-
tion capture (Hodges et al. 2009). These
methods are producing long lists of can-
didate loci that will need to be validated
acrossmanyDNA samples. Bisulfite Patch
PCR provides an efficient workflow to use
second-generation sequencing to follow
up and validate aberrant methylation at
a moderate number of loci (50–100)
across large numbers of samples. This
method is highly sensitive and integrates
DNA barcoding into the library con-
struction process so that many samples
can be pooled to fully utilize the capac-
ity of next-generation sequencing. We
designed the method so that it is easy to implement in any labo-
ratory, has an easy workflow that does not involve shotgun library
construction, and requires small amounts of sample DNA. The
method specifically targets and selects loci before sodium bisulfite
treatment, which increases the specificity and decreases the oligo
cost and design failures compared with similar methods that select
after bisulfite conversion (Hodges et al. 2007; Ball et al. 2009; Deng
et al. 2009). Bisulfite Patch PCR should have broad utility for the
investigation of DNA methylation across disciplines, including
cancer and other disease research, stem cell research, aging re-
search, population-based studies of natural variation, and epide-
miological studies of environmental exposures.
There are a few constraints and unknown parameters of the
method that are important to note. The boundaries of target loci
are defined by restriction digest. This is a design constraint that
limits the number of loci that can be targeted in a single reaction,
either because the regions do not contain restriction sites or be-
cause the restriction cut occurs in a repetitive element and a unique
patch oligo cannot be designed. We chose to use the restriction
enzyme AluI because it is not sensitive to methylation, it is an ef-
ficient enzyme, it has a four-base recognition sequence so it cuts
frequently in the genome, and it cuts the middle of its recognition
sequence and leaves blunt fragments, so there is not concern about
imprecise cut positions.We computationally determined that 59%
(161/271) of CAN gene promoters could be targeted with the
current design criteria using AluI restriction, and picked 94 of these
for this experiment (see section Design of Patch Oligonucleotides
and Universal Primers). We also computed the optimal restriction
enzyme pair that produces themost restriction fragments from the
CAN gene promoters. We determined that 71% of the CAN genes
Table 2. Promoters exhibiting tumor-specific methylation
Gene promoters exhibiting tumor-specific hypermethylation in both
breast and colon tumors are shaded in blue. Gene promoters exhibiting
tumor-specific hypermethylation in one tumor type are shaded in yellow.
Gene promoters exhibiting tumor-specific hypomethylation in both
breast and colon tumors are shaded in green. The probability of meth-
ylation being tumor specific was calculated using the Fisher’s exact test.
Figure 5. Allelic tumor-specific methylation. Data from six patients who are germline heterozygous
for a SNP (rs2854744) in the IGFBP3 promoter. The sequencing reads are aligned as rows in each panel.
Each base in the read is color-coded to indicate the sequence: (yellow) a methylated cytosine; (blue) all
other bases. The position of the SNP is indicated by the red and white column: (red) reads from the A
allele; (yellow) methylated C allele; (white) C allele, if unmethylated and converted to a T. Patient
‘‘breast 8’’ is unmethylated on both alleles in both the tumor (left column) and normal tissue (right
column). Patients ‘‘breast 4’’ and ‘‘colon 6’’ display tumor-specific methylation on only one allele, and
the methylated allele differs between them. Patients ‘‘colon 7’’ and ‘‘colon 12’’ display tumor-specific
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promoters could be targeted using a double digest of Tsp509I and
HaeIII. To further improve the number of loci that can be targeted,
separate restriction digests could be performed on aliquots of the
sample gDNA, and the DNA could be repooled for the subsequent
patch ligation and PCR. For example, if an AluI digest was per-
formed in one tube, a Tsp509I/HaeIII double digest was performed
in a second tube, and the reactions were pooled for the patch li-
gation, then 83% of CAN gene promoters could be targeted.
The development of a way to specifically cleave the DNA at the
boundaries of the targeted loci would significantly improve the
design success rate of the method. One unknown parameter for
the method is the number of loci that can be amplified in a single
reaction. As the capacity of next-generation sequencing machines
expands, it will be logical to expand the level of multiplexing
achieved by Bisulfite Patch PCR. Sincewe successfully amplified all
94 of the targeted loci in this initial experiment, we have not de-
termined the limit to increasing numbers of targeted loci. Addi-
tionally, as more loci are targeted, the cost of oligo synthesis be-
comes a concern, and methods besides standard oligo synthesis
will need to be explored (Porreca et al. 2007).
In this proof-of-principle experiment, we applied thismethod
to characterize the promoter methylation of genes that are fre-
quently mutated in cancer. From the 94 gene promoters that we
analyzed, we found that ;10% showed tumor-specific DNA meth-
ylation in breast or colon cancer compared with the adjacent
normal tissue. Our data support the previously proposed hypoth-
esis that a relatively small set of genes that are important for tu-
morigenesis are disrupted in multiple ways in cancers, including
frequent epigenetic defects (Chan et al. 2008). We found five loci
that can be used to classify tumor and normal samples with high
sensitivity. Follow-up studies that include larger cohorts, cancer-
free control patients, and peripheral samples from patients with
cancer will help determine if these molecular defects can be useful
biomarkers in the clinic. We also used SNPs in the sequencing data
to observe allele-specific methylation patterns that provide in-
sights into the accumulation of aberrant DNAmethylation during
tumor development. This method would be valuable for compar-
ing the allelic accumulation of methylation across tumors with
different stages and grades to understand the timing of aberrant
methylation.
Undoubtedly, the characterization of individual tumors will
require an integrative approach, since key genes can be disrupted
by numerous defects, including methylation, point mutation, and
genetic instability (The Cancer Genome Atlas Research Network
2008; Chan et al. 2008). While, any individual method does not
provide a complete picture of the spectrum of defects in a tumor,
ideally we will move toward incorporating many different tools to
obtain a comprehensive view of the expression differences, copy
number variation, genome sequence, and epigenetic changes in
each tumor. The method presented here fills a gap in the arsenal
of tools for the characterization of aberrant DNA methylation.
It provides the high resolution of bisulfite sequencing with the
throughput of sampling many loci across many samples. This en-
ables an experimental scale that promises to be useful in the effort
to understand cancer.
Methods
Design of patch oligonucleotides and universal primers
Human promoter sequence between the TSS and 700 bp upstream
of the TSS was downloaded from the March 2006 assembly on the
UCSC Genome Browser (http://www.genome.ucsc.edu) for the
RefSeq genes listed in Supplemental Data 1. These sequences were
then scanned for the AluI restriction enzyme recognition se-
quences, and the AluI restriction fragments that were between
125 bp and 600 bp in length and containing at least three CpG
positions were selected. A patch oligo was then designed by se-
quentially included base pairs from the AluI restriction site into
fragment sequence until the Tm of Patch oligo was between 62°C
and 67°C. Any fragment whose patch oligos contained repetitive
elements according to the RepeatMasker track on the UCSC Ge-
nome Browser (http://www.genome.ucsc.edu)were excluded. The
patch oligos were then appended with the complement universal
primer sequences to result in the appropriate patch sequence.
Patch oligonucleotides were synthesized by SigmaGenosys (http://
www.sigmaaldrich.com/Brands/Sigma_Genosys.html). Ninety-four
pairs of patch oligos were ordered in a 96-well plate. The patch
oligos for two loci were duplicated on the plate so that when the
equimolar portions were pooled from each well, these two loci
were twice as concentrated in the pool. This was used to measure
how the concentration of patch oligos affected amplification ef-
ficiency during protocol development. Two universal primer se-
quences were synthesized by IDT (http://www.idtdna.com), in-
cluding U2, which has a 59 phosphate and a three-carbon spacer
on the 39 end. Oligonucleotide sequences are listed in Supple-
mental Table 3.
Bar coded universal primers are used to PCR amplify the se-
lected bisulfite converted loci from each sample. A different pair of
universal primers is used to PCR amplify each sample, and they are
distinguished by a 5-bp sample-specific DNA barcode that resides
between the universal primer sequence and the 454 machine-
specific sequence. The universal primer sequence is listed in Sup-
plemental Table 3, and the barcode used for each patient sample is
listed in Supplemental Table 2. There are 1024 possible 5-bp DNA
sequences. We first excluded barcodes that contained homopoly-
mers since 454 sequencing is known to producemore errors in this
sequence context. We then calculated the number of sequence
differences between all possible pairs of barcodes. We selected 48
sample-specific barcodes, one for each sample that had the least
sequence similarity to each other, so that PCR error or sequencing
error was least likely to turn one barcode sequence into another,
resulting in the misassignment of a read to the wrong patient. We
then ordered the 48 universal primer pairs containing barcodes
from IDT (http://www.idtdna.com).
Bisulfite Patch PCR
Genomic DNA from cancer and adjacent normal tissue was
obtained from Biochain (http://www.biochain.com) for both the
breast and colon . Patient information and lot numbers are listed in
Supplemental Table 2. Each patient sample was aliquoted into a
well of a 96-well plate and digested with the AluI restriction
endonuclease in 10 mL of total volume reaction containing 250
ng DNA, 10 U of AluI enzyme (NEB), and 13 NEBuffer 2 (NEB).
This reaction was incubated for 1 h at 37°C, followed by heat
inactivation of the enzyme for 20min at 65°C, andwas held at 4°C
until the subsequent step.
Patch driven ligation of the universal primers to selected
fragments was performed by addition of more reactants to the
initial tube to result in the following final concentrations: 2 nM
each Patch oligo, 200 nM U1 primer, 200 nM U2 primer (contains
59 phosphate and 39 three carbon spacer), 5 U of Ampligase (Epi-
centre), and 13 Ampligase Reaction Buffer (Epicentre) in a total
volume of 25 mL. This reaction was incubated for 15 min at 95°C,
followed by 30 sec at 94°C and 8 min at 65°C for 100 cycles, and
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Incorrect products, template genomic DNA, and excess primer
were degraded by the direct addition of 10U of exonuclease I (USB)
and 200 U of Exonuclease III (Epicentre) to the reaction. This mix
was incubated for 1 h at 37°C, followed by heat inactivation for
20 min at 95°C, and was held at 4°C.
The reactions were then treated with sodium bisulfite to
convert unmethylated cytosines to uracil. This was achieved by
using the EZ DNAMethylation Gold Bisulfite Treatment Kit (Zymo
Research) following the manufacturer’s instructions, with one ex-
ception. Since the sample volume after the exonuclease treat-
ment is 27 mL, the CT Conversion Reagent from the kit is made by
adding 830 mL of dH2O instead of 900 mL of dH2O. The DNA is
eluted from the columns in the final step with 10 mL of M-Elution
buffer.
For the Universal PCR, we added reagents to the 10 mL
of column elution to result in these final concentrations in 50 mL:
0.5 mM 454A:Sample Specific Barcode:U1, 0.5 mM 454B:Sample
Specific Bar code:U29, 10 U of Platinum Taq polymerase (Invi-
trogen), 0.5 mM each dNTP, 2 mM MgCl2, 0.5 M Betaine, 20 mM
Tris-HCl (pH 8.4), and 50 mM KCl. This reaction was incubated
for 2 min at 93°C, followed by 30 sec at 93°C and 6 min at 57°C
for 35 cycles, andwas held at 4°C. The PCR product smear between
the expected sizes was confirmed by running 20 mL of the PCR
product from each sample on a 3% Metaphor agarose gel (Lonza).
We then pooled 5 mL from each sample into a single tube and
purified this pool on a Qiaquick Spin Column (Qiagen). The eluted
DNA was quantified on the NanoDrop (http://www.nanodrop.
com) as well as on a plate reader (BioTek Synergy HT) using Pico-
Green (Invitrogen) following themanufacturer’s instructions. This
pooled sample was then prepared and sequenced on the 454
Life Sciences (Roche) FLX machine following the manufacturer’s
instructions.
Sequencing data analysis
Weobtained 97,115 sequencing reads, with an average read length
of 228 bp. The sequence reads and quality scores are available in
a gzipped fastq format file (Supplemental Data 2). To determine
which sequencesmatched our targets, we aligned the reads against
a database of reference sequences for each target using WU-
BLASTN (http://blast.wustl.edu). Since the sequences are sodium
bisulfite–treated, we substituted a T in place of C in the genomic
sequence at the non-CpG positions in the reference sequences.We
then determined how many reads matched significantly to each
promoter (BLAST smallest sum P < 0.001) and put all reads from
each promoter in a separate file. We computed the correlation
between the number of reads and the amplicon length for each
promoter using linear regression.We identifiedwhich sample each
read came from by matching the first five bases of the read to the
list of sample-specific barcode and corresponding patients. To de-
termine the reproducibility of the method, we computed the
number of reads for each locus in each sample, and calculated the
correlation coefficient between two samples for all possible pairs of
samples; the mean of these correlation coefficients represents the
average correlation between the number of reads per locus across
samples. For each promoter, we used ClustalW to generate multi-
ple sequence alignments of all of the reads and the reference se-
quence (Larkin et al. 2007). We identified germline SNPs in the
sequences by looking for variants in the reads and comparing these
to known SNPs reported on the UCSC Genome Browser (http://
www.genome.ucsc.edu). To visualize these multiple sequence
alignments, we create one matrix per promoter, where the first
column identifies the sample from which the read originated
(1–48), and the remaining columns are coded for the base in the
read, where Cs are replaced with 8, the two alleles at SNP positions
are replaced with 5 and 12, and the remaining bases are converted
to 0. This matrix was then visualized as an image using the
Matlab software package (The Mathworks, Inc.). The matrix was
sorted by sample type (the first column) and further calculations
regarding the amount of methylation per read, and per sample
were computed using Matlab (The MathWorks, Inc.).
To quantify the sensitivity and specificity of each locus ex-
hibiting tumor-specific methylation, we used a threshold to clas-
sify a locus as methylated or unmethylated in each sample. We
queried many CpGs for each locus with the bisulfite sequenc-
ing. We used this information to find the optimal classifier of
DNA methylation to distinguish tumor and normal samples. We
searched across all possible values for two parameters: percentage
of CpGs per molecule and percentage of reads per sample. We
found that the optimal classifier between tumor and normal was to
classify a sample as ‘‘methylated’’ if more than 20% of CpG posi-
tions per molecule were methylated in more than 35% of mole-
cules. The fraction of samples that were classified as methylated is
listed in Table 2 for each locus.
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